Molecular aspects of medicineApr 17, 2026

Anti-inflammatory effects of glucagon-like peptide-1 receptor activators

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 18, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may alleviate inflammation-related diseases.

GLP-1RAs are associated with signal transduction across various tissues due to widespread receptor expression.
In addition to metabolic benefits, GLP-1RAs could have anti-inflammatory effects.
Potential diseases that may benefit from enhanced GLP-1 signaling include cardiovascular disorders, metabolic associated steatohepatitis, neurodegenerative illnesses, arthritis, and inflammatory bowel disease.
The findings suggest a broader clinical application of GLP-1RA medications for inflammatory conditions.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can ignite the downstream signal transduction in various tissues/organs due to the receptor expression across cell types, thus playing multifaceted biological roles in and beyond anti-diabetes. Besides metabolic benefits, anti-inflammatory pathology is emerging as an attractive mode to inspire expanding therapeutic utilities of GLP-1RAs, through the synergistic cellular/molecular mechanisms of modulating meta-inflammation or immuno-metabolism. Thus this article presents a trending profile of representative inflammation-mediated diseases which are likely to be alleviated upon pharmacological augmentation of GLP-1 signaling, including cardiovascular disorders, metabolic associated steatohepatitis, neurodegenerative illness, arthritis and inflammatory bowel disease. Insights herein tend to systemically highlight an ongoing translation from the comprehensive GLP-1 effects on multiple organs into greater clinical application of GLP-1RA medication for inflammatory indications.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Conflict of interest The author declares no conflict of interest. No funding was needed for this study. No intellectual property issue in the study. This work has not previously been published elsewhere.

PubMed

Anti-inflammatory effects of glucagon-like peptide-1 receptor activators

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief